Novavax (NVAX) Has 'Substantial Doubt' About Its Future

Novavax (NVAX) has 'substantial doubt' about its future. Caleb Silver discusses NVAX as its earnings were released February 28th. NVAX's adjusted EPS came in at -$2.28 versus an estimated -$0.92 and its revenue came in at $357.40M versus an estimated $377.64M. He talks about how NVAX warned of funding concerns and plans to reduce spending. He also goes over iShares Biotechnology ETF (IBB). Tune in to find out more about the stock market today.

Trading 360

03 Mar 2023

SHARE

ON AIR
12:00 am
Fast Market
replay
ON AIR
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
education
7:00 pm
Your First Trade
REPLAY
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now